Anticancer treatments and photosensitivity
Author:
Open Access
- 23 June 2022
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (S6) , 51-58
Abstract
Drug‐induced photosensitivity is associated with a wide range of anticancer treatments, including conventional chemotherapeutic agents, targeted anticancer therapies, and immune checkpoint inhibitors. These dermatologic adverse events can have a major impact on the well‐being and quality of life of cancer patients, leading to dose modifications and interruption or discontinuation of anticancer treatments in severe cases. However, the heterogeneous nature of the photosensitive reactions induced by these agents, as well as the common concomitant use of other potentially photosensitizing drugs (antibiotics, voriconazole, nonsteroidal anti‐inflammatory drugs, etc.), can make the diagnosis and, therefore the prevention, of these adverse events particularly challenging. The aim of this review is to describe the most characteristic forms of photosensitivity observed in patients being treated with anticancer treatments, including phototoxicity and photoallergy, and other potentially photo‐induced manifestations such as UV recall, exaggerated sunburn reactions associated with treatment‐related vitiligo, drug‐induced cutaneous lupus erythematosus, and UV‐induced hyperpigmentation. We also discuss the photosensitive reactions recently reported with new‐generation targeted anticancer therapies and immune checkpoint inhibitors and highlight the importance of continued surveillance to identify photosensitizing agents, and of educating patients on the need for preventive UVA/UVB photoprotective measures.Keywords
This publication has 49 references indexed in Scilit:
- Anomalies pigmentaires induites par les traitements anticancéreux. Première partie : les chimiothérapiesAnnales de Dermatologie et de Vénéréologie, 2013
- Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patientsAnnals of Oncology, 2013
- Ultraviolet A and Photosensitivity during Vemurafenib TherapyNew England Journal of Medicine, 2012
- A systematic review of drug-induced subacute cutaneous lupus erythematosusBritish Journal of Dermatology, 2010
- Cutaneous Pigmentation After Photosensitivity Induced by Vandetanib TherapyArchives of Dermatology, 2009
- Ultraviolet recall reaction after total body irradiation, etoposide, and methotrexate therapyJournal of the American Academy of Dermatology, 2007
- Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesisExpert Opinion on Investigational Drugs, 2007
- Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancerClinical and Experimental Dermatology, 2005
- Imatinib mesylate causes hypopigmentation in the skinCancer, 2003
- Cutaneous photosensitivity diseases induced by exogenous agentsJournal of the American Academy of Dermatology, 1995